Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.